CytoDyn’s Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’ Sep 23, 2020 12:53am EDT
CytoDyn’s CEO Dr. Pourhassan and CMO Dr. Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020 Sep 20, 2020 9:14pm EDT
CytoDyn to Hold Conference Call on September 16 to Provide Update on Discussions with FDA and MHRA for COVID-19 and FDA Meeting on BLA Filing Sep 10, 2020 4:50pm EDT
U.K. MHRA Grants Meeting to CytoDyn to Discuss Fast Track Approval of Leronlimab for COVID-19 Patients Sep 02, 2020 4:01pm EDT
CytoDyn to Hold Conference Call on September 2 to Provide Update on Timelines for Multiple Regulatory and Clinical Initiatives Including COVID-19 Potential Approvals Aug 28, 2020 4:37pm EDT
CytoDyn Reaches Enrollment of 195 Patients in its Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms Aug 25, 2020 8:48pm EDT
After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.’s MHRA Accepts CytoDyn’s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms Aug 20, 2020 4:51am EDT
To Avoid Delay, the FDA Recommends CytoDyn Conduct Its Type A Meeting in Writing with FDA Response Goal Date of September 4 Aug 20, 2020 3:36am EDT
CytoDyn Announces Upcoming Retirement of Dr. David Welch from its Board of Directors Aug 19, 2020 2:44am EDT
